You are here

  • Home
  • Archive
  • Volume 70, Issue 2
  • No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir

Article info

Article menu
Download PDFPDF
Hepatology
Original research
No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir

Authors

  • Feng Su Division of Gastroenterology, University of Washington, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Kristin Berry Health Services Research and Development, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • George N Ioannou Division of Gastroenterology, University of Washington, Seattle, Washington, USA Health Services Research and Development, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, USA Division of Gastroenterology, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Feng Su, University of Washington, Seattle, WA 98195-0005, USA; fsu{at}medicine.washington.edu
View Full Text

Citation

Su F, Berry K, Ioannou GN
No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir
Gut 2021;70:370-378.

Publication history

  • Received September 15, 2019
  • Revised March 15, 2020
  • Accepted March 17, 2020
  • First published March 30, 2020.
Online issue publication 
January 07, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.